Wegovy 0.5 mg click chart: reading your second pen correctly

What the official titration schedule says about 0.5 mg

The Wegovy dosing pathway is defined in the medicine's Summary of Product Characteristics and described in plain terms by NHS England's guidance on weight-management injections. The sequence runs: 0.25 mg for four weeks, then 0.5 mg for four weeks, then 1.0 mg, then 1.7 mg, reaching 2.4 mg as the standard maintenance dose. The 0.5 mg step sits at the second rung of this ladder. Its job is to give your system a controlled, incremental increase rather than jumping straight to a therapeutic level, which is why the earliest weeks exist at all. Gastrointestinal side effects tend to be most noticeable when a new dose begins; a slower climb reduces that burden for most people.

The STEP 1 trial, published in the New England Journal of Medicine, demonstrated average weight reductions of around 15% over 68 weeks at the 2.4 mg maintenance dose. The 0.5 mg step is not where clinically significant weight change is expected (that builds gradually as the dose reaches maintenance) but tolerability at this stage shapes whether a person reaches 2.4 mg at all. Getting comfortable with the pen technique here matters.

Your prescriber decides when, and whether, each step up happens. If nausea or other side effects are significant at 0.5 mg, the prescriber may extend that phase rather than advancing on the standard schedule. That is a clinical decision, not a failure of the medicine.

Reading the 0.5 mg pen: the click explained

Unlike insulin pens, which have a rotating dose selector, the Wegovy pen has a fixed, factory-set dose. There is no click chart in the sense of counting audible clicks to measure a quantity, each pen contains one strength only, and one press delivers it entirely. The phrase "click chart" most often refers to two things: the click you feel and hear when the injection button is fully depressed, and the secondary confirmation click that signals the dose is complete.

The technique is straightforward. Remove the pen cap, attach the needle, prime if it is your first use (follow the steps in the patient information leaflet), choose your injection site (abdomen, thigh or upper arm, rotating each week), press the pen firmly against the skin, push the button until you hear or feel the first click, then hold for six seconds before removing. The second sound or sensation at the end of those six seconds confirms the full dose has been delivered. If you are uncertain about whether the dose went in, contact your prescriber rather than injecting again.

Storage matters too: the pen is kept refrigerated between 2°C and 8°C until it is opened. Refer to the patient information leaflet for the exact window during which the pen can be kept at room temperature, that window differs between products and should never be guessed at. If your pen arrived in a DPD-tracked, plain, refrigerated parcel and you stored it promptly, it will be correctly conditioned when you need it.

Side effects to be aware of at the 0.5 mg stage

The side-effect profile at 0.5 mg mirrors the general semaglutide pattern described on the NHS semaglutide medicines page: nausea, loose stools, constipation, indigestion, burping and fatigue are the most commonly reported. They are most noticeable in the days immediately following a dose increase and typically settle within a week or two as the body adjusts. Eating smaller, lower-fat meals and staying well hydrated helps many people manage this phase.

Two situations require prompt medical attention rather than waiting it out. First, severe or persistent stomach pain (particularly pain that radiates toward the back) should be assessed urgently because it can signal pancreatitis, a known but infrequent side effect highlighted in the MHRA's January 2026 Drug Safety Update on GLP-1 medicines. Second, signs of dehydration from repeated vomiting or diarrhoea (dizziness, very dark urine, feeling faint) need medical review. Report any suspected side effects through the MHRA Yellow Card scheme. Your prescriber and the patient information leaflet remain your primary references for side-effect management; nothing on this page replaces that conversation. For a wider look at how costs fit into your treatment decision, the Wegovy pricing overview covers what private treatment typically involves.

Moving beyond 0.5 mg: what comes next and how decisions are made

After approximately four weeks at 0.5 mg, the next planned step is 1.0 mg. The 1.0 mg pen guide covers what changes at that stage. The full progression through each strength is set out on the Wegovy doses page, which is useful to read before your first dose-review conversation. If you want to understand the intermediate step before maintenance, the 1.7 mg pen guide explains what to expect at that stage of the titration. If you are curious about the endpoint (what maintenance actually looks like in practice) the 2.4 mg pen guide explains the final maintenance step.

Decisions about advancing, pausing or staying at any given dose belong to your prescriber. At a clinician-led service like nume, every repeat order is clinically re-reviewed before it is dispensed; no dose change goes through without a prescriber looking at your record. If you are still deciding whether Wegovy is the right route for your situation, the Wegovy overview and the weight-loss treatments page set out the broader picture. When you are ready to have your eligibility assessed by a prescriber, you can check your eligibility through a free consultation, a real clinician reviews it the same day.